

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

VOLUNTARY ANNOUNCEMENT TERMINATION OF COOPERATION WITH ADIMMUNE

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**” or “**Clover**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement (the “**Announcement**”) issued by the Company dated February 20, 2023 in relation to the Exclusive Agreement entered into by and between the Group and Adimmune Corporation (“**Adimmune**”) for Clover to, amongst others, distribute AdimFlu-S (QIS) in mainland China (the “**Cooperation**”). Unless indicated otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board wishes to inform the shareholders and potential investors of the Company that, due to material changes in market conditions and in exercise of the unilateral termination right under the Exclusive Agreement, the Group issued a notice to Adimmune on June 15, 2025 to terminate the Exclusive Agreement with effect from June 30, 2025 (the “**Termination**”). Following the Termination, the Group and Adimmune will cease the Cooperation, and the Group will not distribute AdimFlu-S (QIS) in mainland China.

The Board believes that the Termination will not have a material adverse impact on the Group’s operations. The Group continues with its objectives to advancing the development of its proprietary RSV vaccine candidate SCB-1019 utilized in an RSV re-vaccination setting and as part of a respiratory combination vaccine.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, June 16, 2025

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.